Moore John E, Koulianos Greg, Hardy Margaret, Misawa Naoaki, Millar B Cherie
Department of Bacteriology, Northern Ireland Public Health Laboratory, Belfast City Hospital; School of Biomedical Sciences, Ulster University; Centre for Experimental Medicine, Queen's University, Northern Ireland, UK.
St. David's Poultry Team, Dungannon Enterprise Centre, Northern Ireland, UK.
Int J Mycobacteriol. 2018 Jul-Sep;7(3):265-267. doi: 10.4103/ijmy.ijmy_73_18.
Antimicrobial resistance has rendered certain species of Mycobacterium difficult to treat clinically, particularly the nontuberculous Mycobacterium and Mycobacterium abscessus. While veterinary medicine and human medicine share many classes of antibiotics, there are several antibiotics which are uniquely licensed to veterinary medicine but not human medicine. It was, therefore, the aim of this study to examine the action of eight veterinary antibiotics to a population of multi- and pan-resistant M. abscessus, isolated from the sputum of patients with cystic fibrosis (CF).
Antibiotic susceptibility studies were performed on human clinical isolates of M. abscessus (n = 16), including 11 smooth isolates, 4 rough isolates, and 1 reference isolate (NCTC 13031), against the following 7 veterinary antibiotics (antibiotic class): apramycin (aminoglycoside), cefovecin (cephalosporin), ceftiofur (cephalosporin), framycetin (aminoglycoside), lincomycin (lincosamide), pirlimycin (lincosamide), and spectinomycin (aminocyclitol).
M. abscessus isolates were sensitive (100%) to apramycin and framycetin but resistant (100%) to cefovecin, ceftiofur, lincomycin, pirlimycin, and spectinomycin.
This study identified that the veterinary aminoglycosides, apramycin, and framycetin, have in vitro activity against multi-resistant clinical isolates of M. abscessus. Further studies should now compare the activity of these antibiotics against amikacin and the human aminoglycoside, advocated in the treatment of disease in CF patients, to determine if these novel antibiotics have a future role for the development in human medicine with such chronic disease patients.
抗菌药物耐药性使得某些分枝杆菌在临床上难以治疗，尤其是非结核分枝杆菌和脓肿分枝杆菌。虽然兽医学和人类医学共享许多类抗生素，但有几种抗生素是兽医学特有的许可药物，而不是人类医学的。因此，本研究的目的是检查八种兽用抗生素对从囊性纤维化（CF）患者痰液中分离出的多重耐药和泛耐药脓肿分枝杆菌群体的作用。
对脓肿分枝杆菌的人类临床分离株（n = 16）进行抗生素敏感性研究，包括11株光滑型分离株、4株粗糙型分离株和1株参考分离株（NCTC 13031），针对以下7种兽用抗生素（抗生素类别）：阿普拉霉素（氨基糖苷类）、头孢维星（头孢菌素类）、头孢噻呋（头孢菌素类）、新霉素（氨基糖苷类）、林可霉素（林可酰胺类）、吡利霉素（林可酰胺类）和壮观霉素（氨基环醇类）。
脓肿分枝杆菌分离株对阿普拉霉素和新霉素敏感（100%），但对头孢维星、头孢噻呋、林可霉素、吡利霉素和壮观霉素耐药（100%）。
本研究确定兽用氨基糖苷类药物阿普拉霉素和新霉素对多重耐药的脓肿分枝杆菌临床分离株具有体外活性。现在应进一步研究比较这些抗生素与阿米卡星以及在CF患者疾病治疗中提倡使用的人类氨基糖苷类药物的活性，以确定这些新型抗生素在治疗此类慢性病患者的人类医学发展中是否具有未来作用。
